VanEck Biotech ETF BBH
251.01 USD 0.00 (+0.00%)
At closeNov 6, 2026, 4:00 AM EST
235.72 -15.29 -6.09%
Pre-market · Nov 6, 4:00 AM ET
251.01 Day range 263.74
178.78 52-week range 263.74
- YTD
- +32.63%
- 1 year
- +38.09%
- Market cap
- 516.19M
- EPS (ttm)
- 8.95
- P/E ratio
- 28.04
- YTD return
- +32.63%
- 1-year return
- +38.09%
- Volume
- 27.19K
- Avg volume
- 12.23K
- Open
- 263.74
- Previous close
- 251.01
- Day's range
- 251.01 – 263.74
- 52-week range
- 178.78 – 263.74
1m -12.73 (-4.83%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 167.95
- 200-day average
- 169.82
About VanEck Biotech ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle 
Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps 
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention 
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules 
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications 
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead 
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits - US Judge Weighs Nationwide Ban On Abortion Pills
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' - 5 Top ETFs With Exposure To Biogen
Your note
Sign in to keep a note on BBH — it syncs with the Stock Master app.